FDA approves new indication for Eisai’s Fycompa
WOODCLIFF LAKE, N.J. — Eisai announced Monday that the Food and Drug Administration had given the company approval for a new indication for its seizure treatment Fycompa. The medication has been approved as an adjunctive therapy in treating primary generalized tonic-clonic seizures (PGTC).
The approval of FYCOMPA to treat patients age 12 and older with PGTC seizures represents an important next step toward expanding treatment options for patients whose PGTC seizures are not adequately controlled with their current medication,” Lynn Kramer Eisai’s chief clinical officer and president of Eisai’s Neuroscience and General Marketing Unit, said. “Eisai is committed to advancing epilepsy care and making contributions to help address the diversified needs of epilepsy patients and their families as part of its corporate humane healthcare mission.”
Fycompa is available in 2-, 4-, 6-, 8-, 10- and 12-mg dosage strengths, and patients who are eligible can register at Fycompa.com for a Fycompa savings card.
Teva intros new dosage strength of Focalin XR generic
NORTH WALES, Penn. — Teva announced Monday that it had introduced its generic version of Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules in a new 20-mg dosage strength. The drug, which is used to treat attention deficit hyperactivity disorder, is now available from Teva in 5-, 10-, 15-, 20-, 30- and 40-mg strengths.
“Our customers count on Teva for a continuous supply of new generic products,” Teva’s SVP, U.S. generic sales and marketing Maureen Cavanaugh said. “With the launch of dexmethylphenidate hydrochloride extended-release capsules, CII, in a 20-mg strength we add another quality product to our broad line of affordable generic pharmaceuticals.”
Diplomat acquires Burman’s Specialty Pharmacy
FLINT, Mich. — Diplomat Pharmacy announced Friday that it had acquired the Pennsylvania-based Burman’s Specialty Pharmacy for $72.8 million in cash and $10 million in Diplomat common stock. The acquisition has expanded Diplomat’s hepatitis C specialty services, as Burman’s individualized patient care is focused primarily on those with Hepatitis C.
“Burman's shares our strong commitment to patient care,” Diplomat CEO and chairman Phil Hagerman said. “We acquired Burman's to enhance our targeted clinical management programs, utilize its innovative hepatitis C technology platform and strong payer network, and increase our presence in the U.S. mid-Atlantic region.”
Burman’s uses HealthTrac software, which allows pharmacists and providers to collaborate more on patient care and can be especially helpful for patients with hepatitis C.
“Diplomat's patient-centric focus echoes our own approach,” Steve Burman, president and CEO of Burman’s said. “We pride ourselves on improving patient care with innovative technology. HealthTrac opens the lines of communication between all healthcare professionals involved to improve treatment efficiency in an effort to both improve results and reduce costs. Diplomat shares that vision and puts it into practice with high-touch patient care.”
“We believe the HealthTrac technology will significantly expand our hepatitis C services across our national footprint,” Hagerman said.